View Item 

Show simple item record

Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities
dc.contributor.authorWijarnpreecha, Karn
dc.contributor.authorLi, Fang
dc.contributor.authorLundin, Sori K.
dc.contributor.authorSuresh, Deepika
dc.contributor.authorSong, Michael W.
dc.contributor.authorTao, Cui
dc.contributor.authorChen, Vincent L.
dc.contributor.authorLok, Anna S. F.
dc.date.accessioned2023-05-01T19:10:03Z
dc.date.available2024-06-01 15:09:51en
dc.date.available2023-05-01T19:10:03Z
dc.date.issued2023-05
dc.identifier.citationWijarnpreecha, Karn; Li, Fang; Lundin, Sori K.; Suresh, Deepika; Song, Michael W.; Tao, Cui; Chen, Vincent L.; Lok, Anna S. F. (2023). "Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities." Alimentary Pharmacology & Therapeutics (9): 1014-1027.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/176252
dc.publisherWiley Periodicals, Inc.
dc.titleHigher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176252/1/apt17424.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176252/2/apt17424_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176252/3/apt17424-sup-0004-FigureS3.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176252/4/apt17424-sup-0003-FigureS2.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176252/5/apt17424-sup-0002-FigureS1.pdf
dc.identifier.doi10.1111/apt.17424
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceChang Y, Cho YK, Cho J, Jung HS, Yun KE, Ahn J, et al. Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: a cohort study. Am J Gastroenterol. 2019; 114 ( 4 ): 620 – 9.
dc.identifier.citedreferenceTang A, Ng CH, Phang PH, Chan KE, Chin YH, Fu CE, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs. non-lean NAFLD—a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2022.06.029
dc.identifier.citedreferenceFeldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol. 2017; 112 ( 1 ): 102 – 10.
dc.identifier.citedreferenceKang MK, Park JG. Low skeletal muscle mass is a risk factor for subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Diagnostics (Basel). 2021; 11 ( 5 ): 854. https://doi.org/10.3390/diagnostics11050854
dc.identifier.citedreferenceKuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges. Biomedicine. 2021; 9 ( 10 ): 1346. https://doi.org/10.3390/biomedicines9101346
dc.identifier.citedreferenceArvind A, Henson JB, Osganian SA, Nath C, Steinhagen LM, Memel ZN, et al. Risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease. Hepatol Commun. 2022; 6 ( 2 ): 309 – 19.
dc.identifier.citedreferenceKanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021; 161 ( 5 ): 1657 – 69.
dc.identifier.citedreferenceHagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018; 2 ( 1 ): 48 – 57.
dc.identifier.citedreferenceZou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020; 288 ( 1 ): 139 – 51.
dc.identifier.citedreferenceHa J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022; 26. https://doi.org/10.1016/j.cgh.2022.11.019
dc.identifier.citedreferenceHirose S, Matsumoto K, Tatemichi M, Tsuruya K, Anzai K, Arase Y, et al. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: lean versus overweight patients. PLoS One. 2020; 15 ( 11 ): e0241770.
dc.identifier.citedreferenceLeung JCF, Loong TCW, Wei JL, Wong GLH, Chan AWH, Choi PCL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017; 65 ( 1 ): 54 – 64.
dc.identifier.citedreferenceJang DK, Lee JS, Lee JK, Kim YH. Independent association of physical activity with nonalcoholic fatty liver disease and alanine aminotransferase levels. J Clin Med Res. 2019; 8 ( 7 ): 1013. https://doi.org/10.3390/jcm8071013
dc.identifier.citedreferenceGolabi P, Gerber L, Paik JM, Deshpande R, de Avila L, Younossi ZM. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. JHEP Rep. 2020; 2 ( 6 ): 100171.
dc.identifier.citedreferenceMoon JH, Koo BK, Kim W. Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey. J Cachexia Sarcopenia Muscle. 2021; 12 ( 4 ): 964 – 72.
dc.identifier.citedreferenceLong MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022; 163: 764 – 774.e1. https://doi.org/10.1053/j.gastro.2022.06.023
dc.identifier.citedreferenceDong XC. PNPLA3-a potential therapeutic target for personalized treatment of chronic liver disease. Front Med (Lausanne). 2019; 6: 304.
dc.identifier.citedreferenceLi Y, Xing C, Cohen JC, Hobbs HH. Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology. 2012; 55 ( 1 ): 327 – 8.
dc.identifier.citedreferenceHolmer M, Ekstedt M, Nasr P, Zenlander R, Wester A, Tavaglione F, et al. Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up. Liver Int. 2022; 42 ( 12 ): 2769 – 80.
dc.identifier.citedreferenceStender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017; 49 ( 6 ): 842 – 7.
dc.identifier.citedreferenceMasters RK, Reither EN, Powers DA, Yang YC, Burger AE, Link BG. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. Am J Public Health. 2013; 103 ( 10 ): 1895 – 901.
dc.identifier.citedreferenceByers T. Body weight and mortality. N Engl J Med. 1995; 333 ( 11 ): 723 – 4.
dc.identifier.citedreferenceYounossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64 ( 1 ): 73 – 84. https://doi.org/10.1002/hep.28431
dc.identifier.citedreferenceAlbhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019; 1 ( 4 ): 329 – 41.
dc.identifier.citedreferenceYe Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 ( 8 ): 739 – 52.
dc.identifier.citedreferenceFracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017; 15 ( 10 ): 1604 – 1611.e1.
dc.identifier.citedreferenceYounes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022; 71 ( 2 ): 382 – 90.
dc.identifier.citedreferenceWeinberg EM, Trinh HN, Firpi RJ, Bhamidimarri KR, Klein S, Durlam J, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases. Clin Gastroenterol Hepatol. 2021; 19 ( 5 ): 996 – 1008.e6.
dc.identifier.citedreferenceLi AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020; 14 ( 2 ): 168 – 78.
dc.identifier.citedreferenceAdams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66 ( 6 ): 1138 – 53.
dc.identifier.citedreferenceSemmler G, Wernly S, Bachmayer S, Wernly B, Schwenoha L, Huber-Schönauer U, et al. Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study. Clin Transl Gastroenterol. 2021; 12 ( 4 ): e00326.
dc.identifier.citedreferenceKim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022; 16 ( 2 ): 290 – 9.
dc.identifier.citedreferenceCruz ACD, Bugianesi E, George J, Day CP, Liaquat H, Charatcharoenwitthaya P, et al. 379 characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. Gastroenterology. 2014; 146 ( 5 ): S-909 – S, 909.
dc.identifier.citedreferenceAhmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with Normal body mass index: a population-based study. Clin Gastroenterol Hepatol. 2022; 20 ( 6 ): 1374 – 1381.e6.
dc.identifier.citedreferenceChen VL, Du X, Chen Y, Kuppa A, Handelman SK, Vohnoutka RB, et al. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun. 2021; 12 ( 1 ): 816.
dc.identifier.citedreferenceHsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019; 17 ( 4 ): 630 – 637.e8.
dc.identifier.citedreferenceHagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbæk H, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021; 74 ( 1 ): 474 – 82.
dc.identifier.citedreferenceCalle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348 ( 17 ): 1625 – 38.
dc.identifier.citedreferenceSterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43 ( 6 ): 1317 – 25.
dc.identifier.citedreferenceBurkholder DA, Moran IJ, DiBattista JV, Lok AS, Parikh ND, Chen VL. Accuracy of international classification of diseases-10 codes for cirrhosis and portal hypertensive complications. Dig Dis Sci. 2022; 67 ( 8 ): 3623 – 31.
dc.identifier.citedreferenceCozzolino F, Montedori A, Abraha I, Eusebi P, Grisci C, Heymann AJ, et al. A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project. PLoS One. 2019; 14 ( 7 ): e0218919.
dc.identifier.citedreferenceFloyd JS, Blondon M, Moore KP, Boyko EJ, Smith NL. Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes. Pharmacoepidemiol Drug Saf. 2016; 25 ( 4 ): 467 – 71.
dc.identifier.citedreferenceAndo T, Ooba N, Mochizuki M, Koide D, Kimura K, Lee SL, et al. Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center. BMC Health Serv Res. 2018; 18 ( 1 ): 895.
dc.identifier.citedreferenceWebber BJ, Rogers AE, Pathak SR, Robbins AS. Positive predictive value of an algorithm used for cancer surveillance in the U.S. Armed Forces. MSMR. 2019; 26 ( 12 ): 18 – 22.
dc.identifier.citedreferenceCozzolino F, Bidoli E, Abraha I, Fusco M, Giovannini G, Casucci P, et al. Accuracy of colorectal cancer ICD-9-CM codes in Italian administrative healthcare databases: a cross-sectional diagnostic study. BMJ Open. 2018; 8 ( 7 ): e020630.
dc.identifier.citedreferenceHwang YJ, Kim N, Yun CY, Yoon H, Shin CM, Park YS, et al. Validation of administrative big database for colorectal cancer searched by international classification of disease 10th codes in Korean: a retrospective big-cohort study. J Cancer Prev. 2018; 23 ( 4 ): 183 – 90.
dc.identifier.citedreferenceAbraha I, Serraino D, Montedori A, Fusco M, Giovannini G, Casucci P, et al. Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study. BMJ Open. 2018; 8 ( 7 ): e020627.
dc.identifier.citedreferenceInker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021; 385 ( 19 ): 1737 – 49.
dc.identifier.citedreferenceObesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: 1 – 253, i-xii.
dc.identifier.citedreferenceWHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363 ( 9403 ): 157 – 63.
dc.identifier.citedreferenceDey R, Schmidt EM, Abecasis GR, Lee S. A fast and accurate algorithm to test for binary phenotypes and its application to PheWAS. Am J Hum Genet. 2017; 101 ( 1 ): 37 – 49.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt17424.pdf
Size:
2.504MB
Format:
PDF
View/Open
Name:
apt17424_am.pdf
Size:
4.743MB
Format:
PDF
View/Open
Name:
apt17424-sup-0004-FigureS3.pdf
Size:
25.10MB
Format:
PDF
View/Open
Name:
apt17424-sup-0003-FigureS2.pdf
Size:
52.85MB
Format:
PDF
View/Open
Name:
apt17424-sup-0002-FigureS1.pdf
Size:
16.82MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.